1Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
2Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea.
3Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
4Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
5Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
6Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
7Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
8Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
9Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.
Copyright © 2017 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mechanism and common use | Weight gain | Hypoglycemiaa | HbA1c reduction, %a | Side effects | Caution | |
---|---|---|---|---|---|---|
GLP-1 receptor agonist (exenatide, liraglutide, albiglutide, lixisenatide, dulaglutide) | ↑ Glucose-dependent insulin secretion, ↓ postprandial glucagon secretion, ↓ postprandial hyperglycemia, delay gastric emptying, ↑ satiety | No | No | 0.6–1.9 | GI side effects (nausea, vomiting, diarrhea) | Acute pancreatitis, C-cell hyperplasia, MEN2/MTC family or past history, severe renal or severe bowel disease |
Once or twice daily or once weekly SC injection |
Compound | Brand name | Dosing | |
---|---|---|---|
Short-acting | Exenatde | Byetta | 5–10 µg SC twice daily prior to meals |
Lixisenatide | Lyxumia | 10 µg SC once daily, in the hour before the same meal for 14 days → a fixed maintenance dose of 20 µg once daily | |
Long-acting | Liraglutide | Victoza | 0.6–1.8 mg SC once daily without regard to meals |
Saxenda | BMI ≥30 kg/m2 | ||
BMI 27–30 kg/m2+prediabetes, T2DM, HTN, or dyslipidemia 3 mg daily for 12 weeks | |||
Dulaglutide | Trulicity | 0.75–1.5 mg SC once weekly without regard to meals |
Adapted from Ko et al. [ HbA1c, glycosylated hemoglobin; GLP-1, glucagon-like peptide 1; SC, subcutaneous; GI, gastrointestinal; MEN2, multiple endocrine neoplasia 2; MTC, medullary thyroid cancer. aMonotherapy.
Modified from Korean Diabetes Association [ SC, subcutaneous; BMI, body mass index; T2DM, type 2 diabetes mellitus; HTN, hypertension.